Skip to main content

Affymetrix and Genospectra

Premium

Affymetrix of Santa Clara, Calif., has received US Patent No. 6,953,663, "Polymorphism detection." The patent claims an invention and methods for analyzing polymorphic or biallelic markers, and arrays for carrying out these analyses. Specifically, the claimed methods employ arrays of oligonucleotide probes that are complementary to target nucleic acids that correspond to the marker sequences of an individual. The probes are typically arranged in detection blocks, each block being capable of discriminating the three genotypes for a given marker. The method permits automatable analysis of genetic linkage to polygenic traits.


Affymetrix has also received US Patent No. 6,954,699, "System and method for programmatic access to biological probe array data." The patent claims an application programming interface that includes code libraries. The patent states that the libraries enable the transfer of pixel data, intermediate results data, or both, from a data structure or data file directly or indirectly to a user-provided application. The pixel data and intermediate results data may include data from biological experiments-related probe arrays.


Genospectra of Fremont, Calif., has received US Patent No. 6,953,551, "Microarray fabrication techniques and apparatus." The patent claims a microarray printing system and methods of printing probe microarrays. The system has a print-head formed of one or more capillary bundle, such as light-guiding capillaries. The bundles can be bundles of capillaries that provide a large number of probes on the surface of a substrate. Methods of registering or correlating the distal and proximal ends of the capillaries are also claimed in the patent. Finally, the patent describes methods and equipment for identifying defective microarrays that are missing one or more probes from the surface of the microarray.

 

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.